Surrozen, Inc. (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Purchases 1,034,482 Shares of Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III acquired 1,034,482 shares of the company’s stock in a transaction dated Wednesday, March 26th. The shares were bought at an average cost of $11.60 per share, with a total value of $11,999,991.20. Following the purchase, the insider now owns 795,411 shares of the company’s stock, valued at approximately $9,226,767.60. This trade represents a -432.71 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Surrozen Stock Performance

Surrozen stock opened at $11.01 on Friday. Surrozen, Inc. has a 12-month low of $6.00 and a 12-month high of $18.17. The firm has a 50-day moving average price of $11.37 and a 200-day moving average price of $10.94.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Trustees of Columbia University in the City of New York purchased a new stake in shares of Surrozen during the fourth quarter valued at about $688,000. Stonepine Capital Management LLC increased its holdings in shares of Surrozen by 24.7% in the fourth quarter. Stonepine Capital Management LLC now owns 137,200 shares of the company’s stock valued at $1,969,000 after purchasing an additional 27,200 shares during the period. Stempoint Capital LP raised its position in Surrozen by 91.7% during the 4th quarter. Stempoint Capital LP now owns 350,573 shares of the company’s stock worth $5,031,000 after buying an additional 167,655 shares during the last quarter. Nantahala Capital Management LLC lifted its position in Surrozen by 4.7% during the fourth quarter. Nantahala Capital Management LLC now owns 196,023 shares of the company’s stock valued at $2,813,000 after purchasing an additional 8,817 shares during the period. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in shares of Surrozen in the fourth quarter worth about $928,000. Institutional investors own 66.57% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on SRZN shares. HC Wainwright assumed coverage on shares of Surrozen in a research report on Thursday, January 30th. They set a “buy” rating and a $32.00 price target on the stock. Guggenheim upgraded shares of Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 price target on the stock in a research note on Friday, January 3rd.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.